Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
If Osaka Castle started crumbling, all of Japan would be talking about it. However, in our #Osteoporosis patient survey, 60% of Japanese women over 60 said their healthcare professional had never spoken to them about #osteoporosis or #fragilityfractures.
— UCB News (@ucb_news) 19.10.2018 -
If you’re living with psoriasis and thinking about starting a family, we’re here to offer support: https://t.co/o19MRQOqGj #AIMotherhood https://t.co/kirwhvBlJ9
— UCB News (@ucb_news) 19.10.2018 -
Announcing upcoming UCB #immunology data at #ACR18. We are excited to share the latest news for #AnkylosingSpondylitis #nrAxSpA and #PsA https://t.co/o19MRQOqGj https://t.co/Cn4ZApCM1K
— UCB News (@ucb_news) 19.10.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
